Protalix BioTherapeutics (PLX) FCF Margin (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly FCF Margin came in at 63.0% in Q1 2026, up 11724.0% year-on-year from N/an in Q1 2025, and up 98.46% quarter-over-quarter from 31.75% in Q4 2025.
Protalix BioTherapeutics (PLX) FCF Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 63.0% for Q1 2026.
- On a quarterly basis, FCF Margin rose 11724.0% year-over-year to 63.0% in Q1 2026; TTM through Mar 2026 was 18.84%, a 2241.0% increase from a year earlier, with the FY2025 full-year figure at 23.44%, down 3728.0% from the prior year.
- FCF Margin advanced to 63.0% in Q1 2026 per PLX's latest filing, from 31.75% in the prior quarter.
- Across five years, FCF Margin topped out at 107.84% in Q1 2024 and bottomed at 84.2% in Q2 2022.
- The 5-year median for FCF Margin is 26.61% (2024), against an average of 9.98%.
- Across the five-year window, FCF Margin plunged 18121 bps in 2022 and soared 14251 bps in 2024, its largest moves.
- Year by year, FCF Margin stood at 29.58% in 2022, then soared by 225 bps to 37.0% in 2023, then tumbled by 47 bps to 19.57% in 2024, then jumped by 62 bps to 31.75% in 2025, then soared by 98 bps to 63.0% in 2026.
- Per Business Quant, the three latest PLX FCF Margin figures stand at 63.0% (Q1 2026), 31.75% (Q4 2025), and 25.71% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 63.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.00% |
| Dec 31, 2025 | 31.75% |
| Sep 30, 2025 | -25.71% |
| Jun 30, 2025 | -33.11% |
| Mar 31, 2025 | -54.24% |
| Dec 31, 2024 | 19.57% |
| Sep 30, 2024 | 18.76% |
| Jun 30, 2024 | -26.61% |
| Mar 31, 2024 | 107.84% |
| Dec 31, 2023 | 37.00% |
| Sep 30, 2023 | -70.90% |
| Jun 30, 2023 | 13.82% |
| Mar 31, 2023 | -34.67% |
| Dec 31, 2022 | -29.58% |
| Sep 30, 2022 | -65.77% |
| Jun 30, 2022 | -84.20% |
| Mar 31, 2022 | -36.66% |
| Dec 31, 2021 | -48.78% |
| Sep 30, 2021 | -18.45% |
| Jun 30, 2021 | 97.01% |